Dermata Therapeutics Profit Margin

Dermata Therapeutics (DRMA) currently reports a profit margin of -12811.49% as of September 2026. That is below the Healthcare sector average of 19.13%. Use the charts on this page to explore Dermata Therapeutics's profit margin history and peer comparisons.

Dermata Therapeutics's profit margin of -12811.49% is lower than the Healthcare sector average of 19.13%. That is roughly 67066.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Dermata Therapeutics's current -12811.49% should be judged against Healthcare norms (sector average: 19.13%) and against DRMA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -12811.49%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 19.13%. From there, open related valuation or income-statement pages for Dermata Therapeutics, and consider following DRMA for alerts when major investors trade the stock.

Dermata Therapeutics is classified in the Healthcare sector. On profit margin, it currently shows -12811.49% versus a sector average near 19.13%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DRMA with unrelated industries.